Genedata Expressionist
Mass Spectrometry Data Analysis
Receive your quote directly from the manufacturer.
Genedata Expressionist® is part of the Genedata portfolio of advanced software solutions, which digitalize and automate data-rich and complex biopharma R&D processes. From early discovery all the way to the clinic, Genedata solutions maximize the ROI in R&D expenditure.
Assessing biotherapeutic developability using advanced mass spectrometry workflows
This case study explores how Sanofi uses mass spectrometry (MS) workflows to assess the developability of novel biotherapeutics, focusing on identifying chemical liabilities and key attributes that influence stability, efficacy, and manufacturability. The study highlights the increasing complexity of modern biotherapeutics and the need for high-throughput, data-driven analytical approaches.
Using the Genedata Expressionist platform, Sanofi implemented configurable, automated MS data processing workflows to integrate and analyze complex datasets from multiple instruments and assays. The approach enables improved data transparency, standardization, and scalability, supporting rapid identification of modifications and structural features that may impact product quality. This enhanced analytical capability allows earlier decision-making, reduces development risk, and accelerates the optimization of next-generation therapeutic candidates.
Resource details:
- Resource type: Case study
- Page count: 4
- Read time: 6 mins
Automating MS-based workflows to accelerate antibody-drug conjugate discovery
This case study describes how Merck streamlined antibody-drug conjugate (ADC) discovery by implementing the Genedata Biopharma Platform to automate mass spectrometry (MS)-based workflows. The solution integrates data from multiple analytical techniques, enabling consistent, real-time access to molecular and analytical information across global research sites.
By centralizing data and automating workflows, the platform eliminates manual data handling and reduces the risk of human error. It enables high-throughput processing of ADC samples, automatic calculation of key attributes such as drug-to-antibody ratio (DAR), and improved traceability across the discovery pipeline. This approach supports faster decision-making, improved data accessibility, and more efficient identification of promising ADC candidates.
Resource details:
- Resource type: Case study
- Page count: 2
- Read time: 3 mins
Mass spec data digital transformation at Lilly Biologics Discovery
Thursday, June 11 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
Mass spectrometry (MS) now produces richer, more complex datasets than ever, offering biopharmaceutical teams new opportunities to deepen biological insight and accelerate discovery. Unlocking this potential requires transforming raw MS outputs into structured, automated, and analysis‑ready data that can support scalable workflows, reproducible analytics, and AI‑driven prediction models.
In this SelectScience® webinar, learn from Dr. Joomi Ahn, Senior Director at Eli Lilly, as she shares how the Biologic Discovery Mass Spectrometry group implemented Genedata Expressionist to build an integrated digital ecosystem. By connecting electronic lab notebooks, liquid‑handling automation, and custom artificial intelligence and machine‑learning tools, the team achieved 3–10× productivity gains.
By registering for this webinar, you will hear first‑hand how these capabilities now enable high‑throughput intact mass analysis, bispecific assembly checks, and stability peptide mapping. This flexible, vendor‑neutral foundation can help teams accelerate their workflows and unlock insights that drive the next wave of biologic drug discovery.
What will this webinar cover?
- How to standardize MS workflows across sites with a scalable, vendor-neutral, flexible platform
- How to automate end-to-end MS processes to increase productivity, data integrity, and knowledge access
- How to integrate wet and digital labs to shorten developability timelines for any new and hybrid modality
- How to leverage sequence liability prediction and automated stability reporting to accelerate drug candidate selection
Who should attend?
- Analytical scientists and innovation leaders looking for scalable, vendor-neutral ways to standardize and automate MS workflows across labs and sites.
- Developability and CMC characterization stakeholders using MS data and digital platforms to streamline biologics discovery and development, reduce optimization cycles, and accelerate timelines.
- VP/Director-level biopharma leaders building digital foundations in R&D and evaluating how AI and digital tools can accelerate timelines and deliver measurable impact.
- IT, informatics, and scientific software developers integrating legacy systems, enabling scalable infrastructure, and delivering user-friendly tools that strengthen scientific workflows.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
